Extension of the Cancer Immunotherapy Pilot Program, 58772-58773 [2022-20988]

Download as PDF 58772 Federal Register / Vol. 87, No. 187 / Wednesday, September 28, 2022 / Notices Dated: September 22, 2022. David Mussatt, Supervisory Chief, Regional Programs Unit. Programs Unit at (202) 809–9618. Records and documents discussed during the meeting will be available for public viewing as they become available at www.facadatabase.gov. Persons interested in the work of this Committee are advised to go to the Commission’s website, https://www.usccr.gov, or may contact the Regional Programs Unit at the above email or email address. [FR Doc. 2022–20900 Filed 9–27–22; 8:45 am] BILLING CODE P COMMISSION ON CIVIL RIGHTS Notice of Public Meeting of the Nebraska Advisory Committee to the U.S. Commission on Civil Rights AGENCY: Agenda U.S. Commission on Civil Rights. ACTION: Announcement of meeting. Notice is hereby given, pursuant to the provisions of the rules and regulations of the U.S. Commission on Civil Rights (Commission) and the Federal Advisory Committee Act that the Nebraska Advisory Committee (Committee) to the U.S. Commission on Civil Rights will hold a meeting on Tuesday, October 18, 2022 at 4:00 p.m.– 5:00 p.m. Central Time. The purpose for the meeting is to discuss the proposal for their project on effects of the pandemic on education in the state. DATES: The meeting will take place on Tuesday, October 18, 2022, from 4:00 p.m. –5:00 p.m. Central Time. Online Registration (Audio/Visual): Join ZoomGov Meeting https:// www.zoomgov.com/j/1613334131? pwd=WDMwV2o5QXda NlNBY2gyTkxaNmtJZz09 Telephone (Audio Only): Dial 833 568 8864 USA Toll Free; Access code: 161 333 4131# FOR FURTHER INFORMATION CONTACT: Victoria Moreno at vmoreno@usccr.gov or by phone at 434–515–0204. SUPPLEMENTARY INFORMATION: This meeting is available to the public through the Zoom link above. If joining only via phone, callers can expect to incur charges for calls they initiate over wireless lines and the Commission will not refund any incurred charges. Individuals who are deaf, deafblind and hard of hearing may also follow the proceedings by first calling the Federal Relay Service at 1–800–877–8339 and providing the Service with the conference call number and conference ID number. Members of the public are also entitled to submit written comments; the comments must be received in the regional office within 30 days following the meeting. Written comments may be emailed to Victoria Moreno at vmoreno@usccr.gov. All written comments received will be available to the public. Persons who desire additional information may contact the Regional lotter on DSK11XQN23PROD with NOTICES1 SUMMARY: VerDate Sep<11>2014 18:06 Sep 27, 2022 Jkt 256001 I. Welcome and Roll Call II. Chair’s Comments III. Discuss Project Proposal IV. Next Steps V. Public Comment VI. Adjournment Dated: September 22, 2022. David Mussatt, Supervisory Chief, Regional Programs Unit. [FR Doc. 2022–20902 Filed 9–27–22; 8:45 am] BILLING CODE 6335–01–P DEPARTMENT OF COMMERCE Bureau of Industry and Security Agency Information Collection Activities; Submission to the Office of Management and Budget (OMB) for Review and Approval; Comment Request; Special Priorities Assistance The Department of Commerce will submit the following information collection request to the Office of Management and Budget (OMB) for review and clearance in accordance with the Paperwork Reduction Act of 1995, on or after the date of publication of this notice. We invite the general public and other Federal agencies to comment on proposed, and continuing information collections, which helps us assess the impact of our information collection requirements and minimize the public’s reporting burden. Public comments were previously requested via the Federal Register on June 14, 2022, during a 60-day comment period. This notice allows for an additional 30 days for public comments. Agency: Bureau of Industry and Security, Department of Commerce. Title: Special Priorities Assistance. OMB Control Number: 0694–0057. Form Number(s): BIS–999. Type of Request: Regular submission, revision, and extension of a current information collection. Number of Respondents: 1,200. Average Hours per Response: 30 minutes. Burden Hours: 600. Needs and Uses: The information collected from defense contractors and suppliers on Form BIS–999, Request for PO 00000 Frm 00009 Fmt 4703 Sfmt 4703 Special Priorities Assistance, is required for the enforcement and administration of special priorities assistance under the Defense Production Act, the Selective Service Act and the Defense Priorities and Allocation System regulation. Contractors may request Special Priorities Assistance (SPA) when placing rated orders with suppliers, to obtain timely delivery of products, materials, or services from suppliers, or for any other reason under the DPAS, in support of approved national programs. The Form BIS–999 is used to apply for such assistance. Affected Public: Business or other forprofit organizations. Frequency: On Occasion. Respondent’s Obligation: Voluntary. Legal Authority: Title I of the Defense Production Act. This information collection request may be viewed at www.reginfo.gov. Follow the instructions to view the Department of Commerce collections currently under review by OMB. Written comments and recommendations for the proposed information collection should be submitted within 30 days of the publication of this notice on the following website www.reginfo.gov/ public/do/PRAMain. Find this particular information collection by selecting ‘‘Currently under 30-day Review—Open for Public Comments’’ or by using the search function and entering either the title of the collection or the OMB Control Number 0694–0057. Sheleen Dumas, Department PRA Clearance Officer, Office of the Chief Information Officer, Commerce Department. [FR Doc. 2022–20974 Filed 9–27–22; 8:45 am] BILLING CODE 3510–33–P DEPARTMENT OF COMMERCE Patent and Trademark Office [Docket No.: PTO–P–2022–0031] Extension of the Cancer Immunotherapy Pilot Program United States Patent and Trademark Office, Department of Commerce. ACTION: Notice. AGENCY: On June 29, 2016, the United States Patent and Trademark Office (USPTO) implemented the Cancer Immunotherapy Pilot Program in support of the White House’s National Cancer Moonshot initiative, which sought to accelerate cancer research. The program permits patent applications pertaining to cancer SUMMARY: E:\FR\FM\28SEN1.SGM 28SEN1 lotter on DSK11XQN23PROD with NOTICES1 Federal Register / Vol. 87, No. 187 / Wednesday, September 28, 2022 / Notices immunotherapy to be advanced out of turn for examination. To date, over 880 petitions requesting participation in the pilot program have been filed, and over 650 patents have been granted under the program. In view of the continued interest in the Cancer Immunotherapy Pilot Program, as well as the White House’s reignition of the National Cancer Moonshot initiative, the USPTO is extending the program, with all parameters remaining the same, until January 31, 2023. The USPTO will also continue to evaluate whether to expand the scope of the pilot program and to what extent during this extension period. DATES: Pilot duration: The Cancer Immunotherapy Pilot Program will continue to run until January 31, 2023. Therefore, petitions to make special under the Cancer Immunotherapy Pilot Program must be filed on or before January 31, 2023. FOR FURTHER INFORMATION CONTACT: For questions regarding this pilot program in general, please contact Susy TsangFoster, Senior Legal Advisor, Office of Patent Legal Administration, Office of the Deputy Commissioner for Patent Examination Policy, at 571–272–7711 or susy.tsang-foster@uspto.gov. For questions related to a particular petition, please contact Gary B. Nickol, Supervisory Patent Examiner, at 571– 272–0835 or gary.nickol@uspto.gov; or Brandon J. Fetterolf, Supervisory Patent Examiner, at 571–272–2919 or brandon.fetterolf@uspto.gov, both of Technology Center 1600. SUPPLEMENTARY INFORMATION: On June 29, 2016, the USPTO published a notice for the implementation of the Cancer Immunotherapy Pilot Program. See Cancer Immunotherapy Pilot Program, 81 FR 42328 (Cancer Immunotherapy Notice). The pilot program was designed to support the global fight against cancer. The Cancer Immunotherapy Notice indicated that an applicant could have an application advanced out of turn (accorded special status) for examination without meeting all the current requirements of the accelerated examination program set forth in item VIII of section 708.02(a) of the Manual of Patent Examining Procedure (9th ed., rev. 10.2019, June 2020), if the application contained at least one claim to a method of treating a cancer using immunotherapy and the applicant met other requirements specified in the Cancer Immunotherapy Notice. The Cancer Immunotherapy Notice established that the pilot program would run for 12 months, beginning on June 29, 2016. Over the course of the pilot program, the USPTO has extended VerDate Sep<11>2014 18:06 Sep 27, 2022 Jkt 256001 it four times through notices published in the Federal Register. The most recent notice extended the program until September 30, 2022 and requested public comments on whether to expand the scope of pilot program and whether to extend it. See Extension of the Cancer Immunotherapy Pilot Program and Request for Comments, 87 FR 38714 (June 29, 2022) (Extension Notice). The Office received one written submission containing three comments from a law firm in response to the request for public comments in the Extension Notice. The Office appreciates the thoughtful comments. The submission is posted at https:// www.regulations.gov/document/PTO-P2022-0019-0001/comment. The USPTO is continuing to evaluate whether to expand the program and to what extent. Various stakeholders from around the world—including independent inventors, universities, research institutions, hospitals, medical centers, government agencies, and large and small companies—have filed petitions to participate in the pilot program. To date, over 880 petitions requesting participation have been filed, and over 650 patents have been granted under the pilot program. In view of the continued interest in the pilot program, the USPTO is hereby extending it through January 31, 2023. The extension will enable the program to continue without lapse as the USPTO continues its ongoing evaluation of whether to expand the program and to what extent. The requirements of the pilot program will not be modified at this time. Katherine K. Vidal, Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office. [FR Doc. 2022–20988 Filed 9–27–22; 8:45 am] BILLING CODE 3510–16–P DEPARTMENT OF DEFENSE Department of the Air Force Acceptance of Group Application Under Public Law 95–202 and Department of Defense Directive (DODD) 1000.20 Department of the Air Force, DoD Civilian/Military Service Review Board. ACTION: Notice. AGENCY: Under the provisions of Section 401, Public Law 95–202 and DoD Directive 100.20, the Department of Defense Civilian/Military Service Review Board has accepted an application on behalf of a group known SUMMARY: PO 00000 Frm 00010 Fmt 4703 Sfmt 4703 58773 as ‘‘Former Members of the Free Iraq Forces and Free Iraq Civil Affairs Program Who Served Under Direct Command of U.S. Army and U.S. Marine Corps Units During Operation Iraqi Freedom Across the Iraqi Freedom Theater of Operations During the Period 2002 Through 2018.’’ Persons with information or documentation pertinent to the determination of whether service of this group should be considered active military service to the Armed Forces of the United States are encouraged to submit such information or documentation within 60 days to the DoD Civilian/Military Service Review Board (DoD C/MSRB), 1500 West Perimeter Road, Suite 3700, Joint Base Andrews, MD 20762. FOR FURTHER INFORMATION CONTACT: Mr. John K. Vallario, President, DoD C/ MSRB, at 240–612–5380, john.vallario.1@us.af.mil. Copies of documents or other materials submitted cannot be returned. Adriane Paris, Air Force Federal Register Liaison Officer. [FR Doc. 2022–20980 Filed 9–27–22; 8:45 am] BILLING CODE 5001–10–P DEPARTMENT OF DEFENSE Department of the Navy Certificate of Alternate Compliance for USS AUGUSTA (LCS 34) Department of the Navy (DoN), Department of Defense (DoD). ACTION: Notice of issuance of certificate of alternate compliance. AGENCY: The U.S. Navy hereby announces that a Certificate of Alternate Compliance has been issued for USS AUGUSTA (LCS 34). Due to the special construction and purpose of this vessel, the Admiralty Counsel of the Navy has determined it is a vessel of the Navy which, due to its special construction and purpose, cannot comply fully with the navigation lights provisions of the International Regulations for Preventing Collisions at Sea, 1972 (72 COLREGS) without interfering with its special function as a naval ship. The intended effect of this notice is to warn mariners in waters where 72 COLREGS apply. DATES: This Certificate of Alternate Compliance is effective September 28, 2022 and is applicable beginning September 21, 2022. FOR FURTHER INFORMATION CONTACT: Lieutenant Commander Andrea Liou, JAGC, U.S. Navy, Admiralty Attorney, Office of the Judge Advocate General, Admiralty and Claims Division (Code SUMMARY: E:\FR\FM\28SEN1.SGM 28SEN1

Agencies

[Federal Register Volume 87, Number 187 (Wednesday, September 28, 2022)]
[Notices]
[Pages 58772-58773]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-20988]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Patent and Trademark Office

[Docket No.: PTO-P-2022-0031]


Extension of the Cancer Immunotherapy Pilot Program

AGENCY: United States Patent and Trademark Office, Department of 
Commerce.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: On June 29, 2016, the United States Patent and Trademark 
Office (USPTO) implemented the Cancer Immunotherapy Pilot Program in 
support of the White House's National Cancer Moonshot initiative, which 
sought to accelerate cancer research. The program permits patent 
applications pertaining to cancer

[[Page 58773]]

immunotherapy to be advanced out of turn for examination. To date, over 
880 petitions requesting participation in the pilot program have been 
filed, and over 650 patents have been granted under the program. In 
view of the continued interest in the Cancer Immunotherapy Pilot 
Program, as well as the White House's reignition of the National Cancer 
Moonshot initiative, the USPTO is extending the program, with all 
parameters remaining the same, until January 31, 2023. The USPTO will 
also continue to evaluate whether to expand the scope of the pilot 
program and to what extent during this extension period.

DATES: Pilot duration: The Cancer Immunotherapy Pilot Program will 
continue to run until January 31, 2023. Therefore, petitions to make 
special under the Cancer Immunotherapy Pilot Program must be filed on 
or before January 31, 2023.

FOR FURTHER INFORMATION CONTACT: For questions regarding this pilot 
program in general, please contact Susy Tsang-Foster, Senior Legal 
Advisor, Office of Patent Legal Administration, Office of the Deputy 
Commissioner for Patent Examination Policy, at 571-272-7711 or 
[email protected]. For questions related to a particular 
petition, please contact Gary B. Nickol, Supervisory Patent Examiner, 
at 571-272-0835 or [email protected]; or Brandon J. Fetterolf, 
Supervisory Patent Examiner, at 571-272-2919 or 
[email protected], both of Technology Center 1600.

SUPPLEMENTARY INFORMATION: On June 29, 2016, the USPTO published a 
notice for the implementation of the Cancer Immunotherapy Pilot 
Program. See Cancer Immunotherapy Pilot Program, 81 FR 42328 (Cancer 
Immunotherapy Notice). The pilot program was designed to support the 
global fight against cancer. The Cancer Immunotherapy Notice indicated 
that an applicant could have an application advanced out of turn 
(accorded special status) for examination without meeting all the 
current requirements of the accelerated examination program set forth 
in item VIII of section 708.02(a) of the Manual of Patent Examining 
Procedure (9th ed., rev. 10.2019, June 2020), if the application 
contained at least one claim to a method of treating a cancer using 
immunotherapy and the applicant met other requirements specified in the 
Cancer Immunotherapy Notice.
    The Cancer Immunotherapy Notice established that the pilot program 
would run for 12 months, beginning on June 29, 2016. Over the course of 
the pilot program, the USPTO has extended it four times through notices 
published in the Federal Register. The most recent notice extended the 
program until September 30, 2022 and requested public comments on 
whether to expand the scope of pilot program and whether to extend it. 
See Extension of the Cancer Immunotherapy Pilot Program and Request for 
Comments, 87 FR 38714 (June 29, 2022) (Extension Notice). The Office 
received one written submission containing three comments from a law 
firm in response to the request for public comments in the Extension 
Notice. The Office appreciates the thoughtful comments. The submission 
is posted at https://www.regulations.gov/document/PTO-P-2022-0019-0001/comment. The USPTO is continuing to evaluate whether to expand the 
program and to what extent.
    Various stakeholders from around the world--including independent 
inventors, universities, research institutions, hospitals, medical 
centers, government agencies, and large and small companies--have filed 
petitions to participate in the pilot program. To date, over 880 
petitions requesting participation have been filed, and over 650 
patents have been granted under the pilot program. In view of the 
continued interest in the pilot program, the USPTO is hereby extending 
it through January 31, 2023. The extension will enable the program to 
continue without lapse as the USPTO continues its ongoing evaluation of 
whether to expand the program and to what extent. The requirements of 
the pilot program will not be modified at this time.

Katherine K. Vidal,
Under Secretary of Commerce for Intellectual Property and Director of 
the United States Patent and Trademark Office.
[FR Doc. 2022-20988 Filed 9-27-22; 8:45 am]
BILLING CODE 3510-16-P